did any one see this headline?
Sentiment: Strong Buy
Regardless of the Mfg process, if the drug is approved they will invest the money to get the process up to speed for production. Who would invest millions into a process that we don't know if it will be or not be approve. I think the key here is the FDA have to give its approval and Sarepta will kick it into gear for the next step.
Fact or not, I am long and don't get me wrong. It does not look like any news is going to make us jump other than we are shipping or starting to see stuff in the market. These guys are F-up again and that why we are not getting any bounce on any news that they are throwing out right now. They need to start making and selling this #HIt already.
Don't know what kind of highlights it will be, but anything would be much better than keeping us in the dark all this time. Maybe the CEO is showing us he is actually doing something vs. just collecting his pay check like Ed & Damage.
Vical is using this same technology in their melanoma treatment and they are in phase III and their finding is about to be release this month. What do you think of their chances?
The price is not moving up or down much, but there sure is a lot of activity after hour for Vical. Does anyone know what is going on? After hours seems to be a lot more active straight across the board for most stocks too.
Is this the reason why we are down today?
Scientists have completed initial tests on a new drug for advanced melanoma and report that it yields positive results in treating this type of malignancy. Melanoma is the most serious form of skin cancer.
A research team from UCLA's Jonsson Comprehensive Cancer Center completed the initial clinical trial of the Merck drug lambrolizumab (MK3475), according to ScienceDaily. They noted positive effects in 135 patients with advanced melanoma.
The National Cancer Institute estimates that more than 45,000 U.S. men and 31,000 women will die in 2013 after developing melanoma of the skin. Healthcare providers classify melanoma as advanced when the skin cancer has spread from the point of origin to another region of the body. Unfortunately, while treatments can extend the lifespan of a patient with advanced melanoma, the disease can't be cured once it has reached that stage, says Cancer Research UK.
The UCLA team reported their findings in the New England Journal of Medicine. They divided patients into three groups and assigned each group a different treatment plan.
Considering all the patients, 38 percent on MK3475 experienced confirmed improvement. Among those on the lowest dose, a quarter had improvement. Of those on the highest, 52 percent improved.
The scientists didn't calculate the average duration of patient response because they removed from the study five subjects with initial responses after their melanoma worsened. So far, the longest response has exceeded a year.
Researchers were encouraged that any side effects were typically mild and easy to manage: fever, fatigue, muscle weakness, loss of skin color, and skin rash. More severe side effects like kidney or lung inflammation affected 13 percent of the subjects.
According to researcher Dr. Antoni Ribas, UCLA professor of medicine, the trial showed that lambrolizumab had the greatest rate of durable responses among any of the drugs tested for melanoma. Experts believe the drug works by reactivating the imm
The FDA is approving GSK drug. We need to get in there. Move it already.
Did anyone saw that or care? All I got is 29 shares DAMMMMMMM 201K share at $439.66 that is #$%$ load of money.
I am also enjoying the bounces too, but for you to claim that because of your present this stock bounces. Not too sure. If you are just a pumper we have plenty of those here and they seems to make the mater worst. I think new management have steer us into the right direction with the removal of that stupid pill and the rest are about to fall in place. Stick around, but don't take all the credit!
07) Most if not all school are now approving IPads to replace text books. Everyone is going to get one! That is IPad not Tablets from Samsung.
I am sure there are plenty of longs here, we just don't care to pump every few second like you two! When the good news hit we will fly, don't need to pump to be true long.
As previously disclosed by Insmed Incorporated (the "Company") in its Annual Report on Form 10-K for the year ended December 31, 2012 (the "Annual Report), the Company entered into an agreement with Premacure AB, now Shire plc, ("Premacure") in May 2012 pursuant to which the Company granted Premacure an exclusive, worldwide license to develop, manufacture and commercialize IGF-1, with its natural binding protein, IGFBP-3, for the prevention and treatment of complications of preterm birth (the "Premacure License Agreement"). As further disclosed in the Annual Report, in March 2013, the Company amended the Premacure License Agreement to provide Premacure with an option to obtain all of the Company's right to receive revenues from the commercialization of IGF-1 under the Premacure License Agreement in exchange for a cash payment to the Company of $11.5 million (the "Buyout Amount").
Premacure exercised this option on April 29, 2013. Premacure is obligated to pay the Buyout Amount to the Company in full within ten days after the date of exercise. As a result of option exercise, the Company will not be entitled to any future royalties from Premacure, and Premacure will assume the Company's royalty obligations to other parties
It is time for the new CEO to show investor that he is actually doing some kinda work. He can't follow Martin and ED freakeen sitting there all day and collect a paycheck. Come-on now!
would this help our caused or gives us more believers in this type of therapy inhttp://news.yahoo.com/roche-immune-therapy-cancer-drug-shows-promise-early-190305365--finance.html
They sound as if they are very supportive of A7. This is good!